Shares of Ascendis Pharma A/S (ASND) surged more than 11% in pre-market trading on Thursday, propelled by a set of positive catalysts. The biopharmaceutical company reported better-than-expected fourth-quarter earnings and announced a share repurchase program, fueling investor enthusiasm for the stock.
Ascendis Pharma reported a Q4 2024 adjusted loss of €0.64 per share, lower than analysts' estimates of a €0.96 loss. The company's revenue for the quarter rose 26.3% year-over-year to €173.92 million, surpassing Wall Street's expectations of €119.71 million. The strong financial performance in Q4 capped off a solid fiscal 2024 for Ascendis Pharma, marked by significant growth in revenue and improving profitability.
Additionally, the company announced that its board has approved a $25 million share repurchase program, further boosting investor confidence. The buyback plan includes the repurchase of up to $18.3 million worth of American depositary shares and a $9 million net settlement of certain restricted stock units. The share repurchase announcement, combined with the upbeat earnings report and a reiterated Buy rating from J.P. Morgan with a price target of $168, fueled the stock's pre-market rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.